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Conclusions.– This suggests that BoNT-A induces spinal plasticity leading to
the recovery of reciprocal inhibition, which is likely to be due to the withdrawal
of inhibitory control from Renshaw cells directly blocked by BoNT-A. This
could help in limiting ankle muscle cocontractions in the transition phase from
stance to swing, to assist dorsiflexion.
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Background.– The therapeutic effects of intramuscular injections of botulinum
toxin type A (BTx) on spasticity can be largely explained by its blocking action
at the neuromuscular junction. BTx is assumed to also have a central action by
affecting the functional organization of the CNS. The aim of the present study is
to assess the action of BTx on spinal motor networks by investigating the post-
activation depression (post-AD) of the soleus H-reflex in post-stroke patients
presenting lower limb spasticity.
Methods.– Soleus H-reflex was investigated in chronic hemiplegic patients
before and 3, 6, 12 weeks after BTx-injections in soleus. H-reflex amplitude
was analyzed in response to electrical stimulation of the tibial nerve at 0.1 Hz
and 0.5 Hz. Post-AD was quantified as the ratio H0.5Hz/H0.1Hz.
Results.– The post-AD was significantly reduced in the affected side compared
to the non-affected side before BTx injection. Three weeks after injection,
the post-AD was reinforced in the paretic leg and significantly higher than in
pre-injection condition.
Conclusions.– BTx-treatment restores the post-AD of soleus H-reflex in post-
stoke paretic patients. As post-AD amount is correlated to the severity of
spasticity, it can be assumed that BTx’s effectiveness in post-stroke rehabilitation
is also due to induced-changes in spinal motor networks.
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Background.– Compare muscle length, spasticity angle and active range of
motion in adult paretic syndromes due to lesions acquired in infancy vs adult-
acquired lesions.
Methods.– Cross sectional study from a retrospective chart review.
Population.– Convenience sample of 2 groups of clinic patients with spastic
paresis due to an infant lesion (IL, n = 11) or to an adult-acquired lesion (AL,
n = 11).
Evaluation.– Muscle length (XV1), angle of catch (XV3), spasticity angle
(X = XV1–XV3), active range of motion (A) and angle of weakness (XV1–A) in
soleus, gastrocnemius, gluteus maximus, hamstrings, vastus and rectus femoris
muscles at the initial evaluation (pre-toxin).
Results.– The IL group had shorter muscle lengths in gluteus maximus (XV1,
IL, 101 ± 5; AL, 120 ± 5◦; P = 0.02, Mann–Whitney) and hamstrings (XV1, IL,
31 ± 7◦; AL, 63 ± 5◦, P = 0.004), smaller spasticity angles (X, gluteus maxi-
mus, IL, 7 ± 3◦; AL, 15 ± 4◦, P = 0.04; hamstrings, IL, 19 ± 4◦ vs AL, 42 ± 7◦,
P = 0.02) and smaller angle of weakness across all muscles studied (P = 0.04,
Wilcoxon). A was strongly correlated with XV1 across all muscles in the IL group
(P < 0.05) while this was only true for plantar flexors and gluteus maximus in
the AL group.
Conclusions.– Passive mechanical obstacles have greater impact on motor defi-
ciencies in infant paresis than in adult acquired lesions.
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Background.– The safety profile of onabotulinumtoxinA for treatment of upper
limb spasticity (ULS) was assessed across a range of doses to evaluate treatment
with ≥ 400 U.
Methods.– Integrated data from 18 studies of onabotulinumtoxinA for ULS were
evaluated by 4 dose groups (< 150 U, 150–250 U, 251–399 U, ≥ 400 U). Treat-
ment exposure, incidence of adverse events (AEs), serious AEs, and possible
distant spread of toxin (PDSOT) were assessed, together with the safety profile of
patients who received 4 consecutive onabotulinumtoxinA ≥ 400 U treatments.
Results.– Overall, 1342 patients received ≥ 1 onabotulinumtoxinA treatment;
183 received ≥ 400 U, with 6.6% (88/1330), 12.3% (115/936), 23.3% (113/486),
and 31.2% (96/308) in treatment cycles 1–4, respectively. AE rates were similar
across dose groups, with no consistent increase in incidence of any individual
AE/serious AE and no evidence of PDSOT at doses ≥ 400 U across treatment
cycles. The overall AE rate among the subset of patients (n = 51) with 4 conse-
cutive ≥ 400 U treatments was similar (43.1%, 43.1%, 43.1%, 41.2%), with no
overall change in profile for AEs/serious AEs with increasing treatments.
Conclusions.– OnabotulinumtoxinA at doses ≥ 400 U was well tolerated in ULS
patients, with no consistent pattern of increase in AEs at doses ≥ 400 U, reported
systemic AEs, or change in safety profile over consecutive treatments.
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Background.– Our study concerns the efficiency of hypnosis during the injections
of botulinum toxin. Hypnosis is widely used in medicine to decrease the anxiety
and the painful felt, but few publications are appeared in physical medicine and
rehabilitation.
Methods.– In this bi-centrique study, the injections are practised at 30 patient’s
spastics. Two groups are constituted: the group “hypnosis” (standards analge-
